Costa DB - Search Results

1

EGFR delE709_T710insD: a rare but potentially EGFR inhibitor responsive mutation in non-small-cell lung cancer.

Ackerman A, Goldstein MA, Kobayashi S, Costa DB. Ackerman A, et al. Among authors: costa db. J Thorac Oncol. 2012 Oct;7(10):e19-20. doi: 10.1097/JTO.0b013e3182635ab4. J Thorac Oncol. 2012. PMID: 22982663 Free PMC article. No abstract available.

2

Are exon 19 deletions and L858R EGFR mutations in non-small-cell lung cancer clinically different?

Costa DB, Kobayashi S. Costa DB, et al. Br J Cancer. 2007 Jan 29;96(2):399; author reply 400. doi: 10.1038/sj.bjc.6603564. Epub 2007 Jan 16. Br J Cancer. 2007. PMID: 17224926 Free PMC article. No abstract available.

3

Immunohistochemical analysis of C/EBPalpha in non-small cell lung cancer reveals frequent down-regulation in stage II and IIIA tumors: a correlative study of E3590.

Costa DB, Li S, Kocher O, Feins RH, Keller SM, Schiller JH, Johnson DH, Tenen DG, Halmos B. Costa DB, et al. Lung Cancer. 2007 Apr;56(1):97-103. doi: 10.1016/j.lungcan.2006.11.023. Epub 2007 Jan 18. Lung Cancer. 2007. PMID: 17239984 Free PMC article.

4

Pooled analysis of the prospective trials of gefitinib monotherapy for EGFR-mutant non-small cell lung cancers.

Costa DB, Kobayashi S, Tenen DG, Huberman MS. Costa DB, et al. Lung Cancer. 2007 Oct;58(1):95-103. doi: 10.1016/j.lungcan.2007.05.017. Epub 2007 Jul 3. Lung Cancer. 2007. PMID: 17610986 Free PMC article.

5

A distal single nucleotide polymorphism alters long-range regulation of the PU.1 gene in acute myeloid leukemia.

Steidl U, Steidl C, Ebralidze A, Chapuy B, Han HJ, Will B, Rosenbauer F, Becker A, Wagner K, Koschmieder S, Kobayashi S, Costa DB, Schulz T, O'Brien KB, Verhaak RG, Delwel R, Haase D, Trümper L, Krauter J, Kohwi-Shigematsu T, Griesinger F, Tenen DG. Steidl U, et al. Among authors: costa db. J Clin Invest. 2007 Sep;117(9):2611-20. doi: 10.1172/JCI30525. J Clin Invest. 2007. PMID: 17694175 Free PMC article.

6

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.

Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. Costa DB, et al. PLoS Med. 2007 Oct;4(10):1669-79; discussion 1680. doi: 10.1371/journal.pmed.0040315. PLoS Med. 2007. PMID: 17973572 Free PMC article.

7

Erlotinib-associated alopecia in a lung cancer patient.

Costa DB, Kobayashi S, Schumer ST. Costa DB, et al. J Thorac Oncol. 2007 Dec;2(12):1136-8. doi: 10.1097/JTO.0b013e31815ba7f9. J Thorac Oncol. 2007. PMID: 18090591 Free article. No abstract available.

8

Response of intracranial metastases to epidermal growth factor receptor tyrosine kinase inhibitors: it may all depend on EGFR mutations.

Costa DB, Kobayashi S. Costa DB, et al. J Clin Oncol. 2008 Feb 1;26(4):686. doi: 10.1200/JCO.2007.15.1944. J Clin Oncol. 2008. PMID: 18235134 No abstract available.

9

Differential responses to erlotinib in epidermal growth factor receptor (EGFR)-mutated lung cancers with acquired resistance to gefitinib carrying the L747S or T790M secondary mutations.

Costa DB, Schumer ST, Tenen DG, Kobayashi S. Costa DB, et al. J Clin Oncol. 2008 Mar 1;26(7):1182-4; author reply 1184-6. doi: 10.1200/JCO.2007.14.9039. J Clin Oncol. 2008. PMID: 18309959 No abstract available.

10

Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.

Costa DB, Nguyen KS, Cho BC, Sequist LV, Jackman DM, Riely GJ, Yeap BY, Halmos B, Kim JH, Jänne PA, Huberman MS, Pao W, Tenen DG, Kobayashi S. Costa DB, et al. Clin Cancer Res. 2008 Nov 1;14(21):7060-7. doi: 10.1158/1078-0432.CCR-08-1455. Clin Cancer Res. 2008. PMID: 18981003 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

200 results

Search Page